3645 results for «569»
3645 results
What bench testing teaches us about real world PCI
19 May 2026 – From EuroPCR 2026
This session explores bench testing insights into real-world percutaneous coronary interventions (PCI). Topics include comparative expansion ratios of coronary stents, prognostic assessments after drug-coated balloon treatments, mechanical performance of magnesium scaffolds in bifurcations, preclinical safety and computational modeling of bioresorbable polymer-coated stents, and evaluations of commonly...
When the anterior leaflet gets in the way: mitral leaflet modification before TMVR
19 May 2026 – From EuroPCR 2026
This session addresses the intricacies of mitral leaflet modification techniques prior to transcatheter mitral valve replacement (TMVR). It features innovative approaches such as LAMPOON-assisted valve-in-ring replacement, balloon-assisted leaflet translocation, and strategies to overcome the challenges posed by mitral annular calcification.
Complication management in CTO PCI - Part 1
19 May 2026 – From EuroPCR 2026
This session addresses complication management during chronic total occlusion (CTO) percutaneous coronary interventions. It covers strategies for unexpected coronary complications, managing tamponade without visible perforation, rescue techniques for atherectomy-related perforations, managing dry pericardial tamponade after septal branch perforation, and challenges when retrograde approaches encounter thrombosis in...
How to face resistent hypertension: when pharmacological treatment is not an option
19 May 2026 – From EuroPCR 2026
Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
